Zenas BioPharma Inc
ZBIOHealthcare|Biotechnology|USA
$28.73
-0.69 (-2.34%)
Tangible Book
$5.38
About
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. The Company manages its operations on a consolidated basis as a single reportable segment focused on the research, development and commercialization of transformative immunology-based therapies.
Stock Price
+138.0%(1Y)
Pipeline Summary
10 total trials4
Phase 1
2
Phase 2
4
Phase 3
0
Phase 4
Active: 3Completed: 3Recruiting: 4
Active Trials (7)
A Phase 3 Study of Obexelimab in Patients With IgG4-Related Disease
NCT05662241IgG4 Related Disease
Phase 3Active
Enrollment: 194 participants
A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis
NCT07067463Multiple Sclerosis (MS) Primary Progressive
Phase 3Recruiting
Enrollment: 705 participants
A Study of Obexelimab in Patients With Relapsing Multiple Sclerosis (MoonStone)
NCT06564311Relapsing Multiple Sclerosis
Phase 2Active
Enrollment: 93 participants
A Study of Obexelimab in Patients With Warm Autoimmune Hemolytic Anemia (SApHiAre)
NCT05786573Warm Autoimmune Hemolytic Anemia
Phase 3Active
Enrollment: 134 participants
A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis
NCT07299019Secondary Progressive Multiple Sclerosis
Phase 3Recruiting
Enrollment: 990 participants
BioScore
5.7/10
Watchlist
Ownership
Recent Insider Trades
MOULDER LEON O JRBUY
2026-05-1860,000 shares @ $16.88
MOULDER LEON O JRBUY
2026-04-2960,000 shares @ $17.79
Lu HongboBUY
2026-03-313,768 shares @ $18.63
Fairmount Healthcare Fund II L.P.BUY
2026-03-31150,000 shares @ $20
MOULDER LEON O JRBUY
2026-03-3154,000 shares @ $18.91
Data last updated: Jul 13, 2026, 12:46 PM